LMX1B

Across TCGA pan-cancer cohorts, LMX1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LMX1B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LMX1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LMX1B expression acts as an unfavorable survival marker.

STAD, HNSC, and UCEC are the cancer types where LMX1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.003	0.660	<.001	12	view →
HNSC	OS	Median	All	0.238	0.686	.031	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LMX1B–STAD (OS)

Open the STAD breakdown →